aTyr Pharma to Present at Upcoming Investor Conferences
aTyr Pharma (Nasdaq: ATYR) has announced its participation in four major investor conferences during November and December 2024. The company will present at the Stifel Healthcare Conference (Nov 18), Jefferies London Healthcare Conference (Nov 20), Evercore HealthCONx Conference (Dec 3), and Piper Sandler Healthcare Conference (Dec 5). The presentations will include corporate presentations and fireside chats across locations in New York, London, and Coral Gables.
Management will be available for one-on-one meetings with registered attendees. Webcasts of the presentations will be accessible on the company's website and remain available for at least 90 days. aTyr is developing first-in-class medicines from its tRNA synthetase platform, with efzofitimod as its lead candidate for treating interstitial lung disease.
aTyr Pharma (Nasdaq: ATYR) ha annunciato la sua partecipazione a quattro importanti conferenze per investitori nel mese di novembre e dicembre 2024. L'azienda presenterà alla Stifel Healthcare Conference (18 nov), Jefferies London Healthcare Conference (20 nov), Evercore HealthCONx Conference (3 dic) e Piper Sandler Healthcare Conference (5 dic). Le presentazioni includeranno presentazioni aziendali e discussioni informali in diverse location a New York, Londra e Coral Gables.
La direzione sarà disponibile per incontri individuali con i partecipanti registrati. Le trasmissioni web delle presentazioni saranno accessibili sul sito web dell'azienda e rimarranno disponibili per almeno 90 giorni. aTyr sta sviluppando medicinali all'avanguardia dalla sua piattaforma di tRNA sintetasi, con efzofitimod come principale candidato per il trattamento della malattia polmonare interstiziale.
aTyr Pharma (Nasdaq: ATYR) ha anunciado su participación en cuatro importantes conferencias de inversores durante noviembre y diciembre de 2024. La empresa presentará en la Stifel Healthcare Conference (18 de noviembre), Jefferies London Healthcare Conference (20 de noviembre), Evercore HealthCONx Conference (3 de diciembre) y Piper Sandler Healthcare Conference (5 de diciembre). Las presentaciones incluirán presentaciones corporativas y charlas informales en ubicaciones en Nueva York, Londres y Coral Gables.
La dirección estará disponible para reuniones uno a uno con los asistentes registrados. Las transmisiones web de las presentaciones estarán disponibles en el sitio web de la empresa y permanecerán accesibles durante al menos 90 días. aTyr está desarrollando medicamentos de primera clase a partir de su plataforma de sintetasas de tRNA, siendo efzofitimod su principal candidato para el tratamiento de la enfermedad pulmonar intersticial.
aTyr Pharma (Nasdaq: ATYR)는 2024년 11월과 12월 동안 네 개의 주요 투자자 회의에 참가할 것이라고 발표했습니다. 이 회사는 Stifel Healthcare Conference (11월 18일), Jefferies London Healthcare Conference (11월 20일), Evercore HealthCONx Conference (12월 3일), Piper Sandler Healthcare Conference (12월 5일)에서 발표할 것입니다. 발표 내용에는 뉴욕, 런던, 코랄게이블스에서의 기업 프리젠테이션과 파이어사이드 채팅이 포함됩니다.
경영진은 등록된 참석자와 일대일 회의를 위해 대기할 것입니다. 발표의 웹캐스트는 회사 웹사이트에서 이용 가능하며 최소 90일 동안 계속 제공될 예정입니다. aTyr는 tRNA 합성효소 플랫폼에서 1세대 의약품을 개발하고 있으며, 인터스티셜 폐질환 치료를 위한 주요 후보로 efzofitimod를 보유하고 있습니다.
aTyr Pharma (Nasdaq: ATYR) a annoncé sa participation à quatre grandes conférences d'investisseurs en novembre et décembre 2024. La société se présentera à la Stifel Healthcare Conference (18 nov.), Jefferies London Healthcare Conference (20 nov.), Evercore HealthCONx Conference (3 déc.) et Piper Sandler Healthcare Conference (5 déc.). Les présentations comprendront des présentations d'entreprise et des discussions informelles dans des lieux à New York, Londres et Coral Gables.
La direction sera disponible pour des réunions individuelles avec les participants inscrits. Les webcasts des présentations seront accessibles sur le site internet de l'entreprise et resteront disponibles pendant au moins 90 jours. aTyr développe des médicaments de première classe à partir de sa plateforme de synthétases d'ARNt, avec efzofitimod comme principal candidat pour le traitement de la maladie pulmonaire interstitielle.
aTyr Pharma (Nasdaq: ATYR) hat seine Teilnahme an vier wichtigen Investorenkonferenzen im November und Dezember 2024 bekannt gegeben. Das Unternehmen wird bei der Stifel Healthcare Conference (18. Nov.), Jefferies London Healthcare Conference (20. Nov.), Evercore HealthCONx Conference (3. Dez.) und Piper Sandler Healthcare Conference (5. Dez.) präsentieren. Die Präsentationen beinhalten Unternehmenspräsentationen und informelle Gespräche an Standorten in New York, London und Coral Gables.
Das Management steht für Einzelgespräche mit registrierten Teilnehmern zur Verfügung. Die Webcasts der Präsentationen werden auf der Website des Unternehmens zugänglich sein und mindestens 90 Tage lang verfügbar bleiben. aTyr entwickelt Arzneimittel der Spitzenklasse aus seiner tRNA-Synthetase-Plattform, wobei efzofitimod als Hauptkandidat zur Behandlung von interstitiellen Lungenerkrankungen fungiert.
- None.
- None.
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present at several upcoming investor conferences scheduled to take place in November and December 2024.
Details of the conferences appear below:
Conference: Stifel Healthcare Conference
Date: Monday, November 18, 2024
Time: 3:35pm EST
Location: New York, NY
Format: Corporate Presentation
Conference: Jefferies London Healthcare Conference
Date: Wednesday, November 20, 2024
Time: 3:00pm GMT
Location: London, UK
Format: Corporate Presentation
Conference: 7th Annual Evercore HealthCONx Conference
Date: Tuesday, December 3, 2024
Time: 8:20am EST
Location: Coral Gables, FL
Format: Fireside Chat
Conference: Piper Sandler 36th Annual Healthcare Conference
Date: Thursday, December 5, 2024
Time: 12:00pm EST
Location: New York, NY
Format: Fireside Chat
In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. A webcast of the presentations will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the events, a replay of the presentations will be available on the aTyr website for at least 90 days. For more information, contact investorrelations@atyrpharma.com.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
| Contact: |
| Ashlee Dunston |
| Director, Investor Relations and Public Affairs |
| adunston@atyrpharma.com |
FAQ
What investor conferences will aTyr Pharma (ATYR) attend in November 2024?
When will aTyr Pharma (ATYR) present at the Evercore HealthCONx Conference 2024?
How long will aTyr Pharma's (ATYR) conference presentation webcasts be available?
What is aTyr Pharma's (ATYR) lead therapeutic candidate mentioned in the announcement?
